Medical Student, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK.
Clinical Lecturer in Neurology, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK.
Scott Med J. 2019 Nov;64(4):126-132. doi: 10.1177/0036933019876155. Epub 2019 Sep 24.
The role of single pill combination therapy for stroke prevention remains to be established. We explored the perspectives of stroke survivors and healthcare professionals on single pill combination therapy for stroke prevention.
We conducted focus groups involving stroke survivors and healthcare professionals.
We recruited six stroke survivors: four (67%) were female and mean age was 70 ± 12 years; and eight healthcare professionals (three Stroke Consultants, two Nurse Specialists, three General Practitioners). Improved adherence is the main perceived benefit of single pill combination therapy, although concerns exist surrounding less individualised care, unsuitability for use in the acute setting, reduced ability to titrate doses and difficulty identifying the cause of side effects. The clinical stability of patients, alongside single pill combination therapy efficacy, cost, side effect profile and evidence base for impact on risk factors and clinical outcomes are key factors influencing acceptability. Stroke survivors and healthcare professionals feel single pill combination therapy is most suitable for stable patients, although there is no evidence base for its use in this context.
Stroke healthcare professionals and stroke survivors are most amenable to using single pill combination therapy for stable patients, although its role in this context should be evaluated in studies with risk factor targets and clinical outcomes as endpoints.
单药联合治疗在预防中风方面的作用仍有待确定。我们探讨了中风幸存者和医疗保健专业人员对预防中风的单药联合治疗的看法。
我们进行了涉及中风幸存者和医疗保健专业人员的焦点小组。
我们招募了六名中风幸存者：四名（67%）为女性，平均年龄为 70±12 岁；和八名医疗保健专业人员（三名中风顾问、两名专科护士、三名全科医生）。改善依从性是单药联合治疗的主要益处，尽管存在个性化护理减少、不适合急性使用、减少剂量调整能力和难以确定副作用原因的担忧。患者的临床稳定性，以及单药联合治疗的疗效、成本、副作用特征以及对风险因素和临床结果的影响的证据基础，是影响可接受性的关键因素。中风幸存者和医疗保健专业人员认为单药联合治疗最适合稳定的患者，尽管在这种情况下，它的使用没有证据基础。
中风医疗保健专业人员和中风幸存者最愿意使用单药联合治疗稳定的患者，尽管在有风险因素目标和临床结果作为终点的研究中，应评估其在这种情况下的作用。
